Free Trial

OmniAb (NASDAQ:OABI) Hits New 12-Month Low - Time to Sell?

OmniAb logo with Medical background

OmniAb, Inc. (NASDAQ:OABI - Get Free Report)'s share price hit a new 52-week low during trading on Saturday . The company traded as low as $3.41 and last traded at $3.44, with a volume of 475446 shares trading hands. The stock had previously closed at $3.57.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Benchmark restated a "buy" rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

Get Our Latest Stock Report on OmniAb

OmniAb Trading Down 3.6 %

The firm has a market cap of $485.78 million, a PE ratio of -5.55 and a beta of -0.10. The business's 50-day simple moving average is $3.87 and its 200 day simple moving average is $4.09.

Institutional Trading of OmniAb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in OmniAb by 6.9% in the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock valued at $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Rice Hall James & Associates LLC grew its position in shares of OmniAb by 6.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company's stock worth $11,515,000 after buying an additional 163,038 shares during the last quarter. State Street Corp grew its position in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company's stock worth $8,594,000 after buying an additional 34,654 shares during the last quarter. Murchinson Ltd. bought a new position in shares of OmniAb during the 3rd quarter worth approximately $4,230,000. Finally, Woodstock Corp lifted its position in OmniAb by 5.6% during the third quarter. Woodstock Corp now owns 792,853 shares of the company's stock valued at $3,354,000 after acquiring an additional 42,310 shares during the last quarter. Institutional investors own 72.08% of the company's stock.

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.

Further Reading

Should You Invest $1,000 in OmniAb Right Now?

Before you consider OmniAb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.

While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Transportation Stocks to Watch in 2025: Top Picks for Growth
Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines